Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,930,000 shares, a decrease of 18.2% from the July 15th total of 2,360,000 shares. Based on an average daily trading volume, of 335,800 shares, the days-to-cover ratio is presently 5.7 days.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of large investors have recently bought and sold shares of KNSA. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter worth $44,000. Rockefeller Capital Management L.P. lifted its stake in shares of Kiniksa Pharmaceuticals by 666.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 5,750 shares of the company's stock valued at $67,000 after buying an additional 5,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kiniksa Pharmaceuticals by 19.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,549 shares of the company's stock valued at $83,000 after buying an additional 1,385 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kiniksa Pharmaceuticals by 290.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,164 shares of the company's stock valued at $84,000 after buying an additional 5,327 shares in the last quarter. Finally, Nisa Investment Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at $86,000. 42.57% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Trading Up 0.4 %

NASDAQ:KNSA traded up $0.05 during trading hours on Monday, reaching $12.46. The company had a trading volume of 281,418 shares, compared to its average volume of 335,599. The business's 50-day simple moving average is $10.44 and its two-hundred day simple moving average is $10.09. Kiniksa Pharmaceuticals has a twelve month low of $7.36 and a twelve month high of $15.24.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Read More

• Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
• The Five Hottest Calls From The Q2 Earnings Season
• Here is a Simple 4 Stock Portfolio that Can Outperform the Market
• Is AMC Entertainment Pulling a Fast One on the APEs?
• Here's How the Inflation Reduction Act Energizes Power Stock
• The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.